Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines by Çalışkan, Ceyda et al.
Vol.:(0123456789) 
Mol Biol Rep (2017) 44:391–397 
DOI 10.1007/s11033-017-4122-3
ORIGINAL ARTICLE
Dishevelled proteins and CYLD reciprocally regulate each other 
in CML cell lines
Ceyda Çalışkan1,2 · Melek Pehlivan1,3 · Zeynep Yüce1 · Ogun Sercan1 
Received: 15 January 2017 / Accepted: 19 August 2017 / Published online: 24 August 2017 
© Springer Science+Business Media B.V. 2017
DVL proteins; our data suggests the presence of a more com-
plicated reciprocal regulatory mechanism in CML cell lines.
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Introduction
The β-catenin/Wnt signaling pathway is critically involved in 
embryogenesis, development, cell proliferation, differentia-
tion, self-renewal and homeostasis. Pathway activation leads 
to β-catenin being stabilized in the cytoplasm and translo-
cated to the nucleus where it regulates the activity of sev-
eral transcription factors [1]. This stabilization is provided 
through an important scaffold protein family called Dishev-
elled proteins (Dvls). In mammals there are three members 
of the Dvl family: Dvl1, -2 and -3. These proteins act as a 
scaffold where other proteins bind and transmit Wnt signals 
to downstream effectors of the Wnt signaling pathway [2, 3]. 
Dvl proteins function in both canonical and non-canonical 
Wnt pathways. They are activated by phosphorylation in 
response to Wnt signaling; whereas the ubiquitination of 
Dvl proteins leads to an effective inhibition of the β-catenin 
destruction complex [4]. It has been postulated that over/
deregulated Dvl expression may play a role in the progres-
sion of several cancers [5–8]. As a result it demonstrates a 
potential target for cancer therapy.
The CYLD (lysine 63 deubiquitinase/ubiquitin carboxyl-
terminal hydrolase/cylindromatosis) gene product is a deu-
biquitinating enzyme. It was first described as a mutated 
gene involved in cylindromatosis and has been classified 
as a tumor suppressor [9]. CYLD is identified as a nega-
tive regulator of several signaling pathways including the 
NF-κB pathway [10] and Dvl mediated signaling [11]. 
Abstract Dishevelled (Dvl) proteins are activated by Wnt 
pathway stimulation and have crucial roles in the regulation 
of β-catenin destruction complex. CYLD is a tumor sup-
pressor and a deubiquitination enzyme. CYLD negatively 
regulates the Wnt/β-catenin signaling pathway by deubiq-
uitinating Dvl proteins. Loss of function and mutations of 
CYLD were linked to different types of solid tumors. Loss 
of function in CYLD is associated with Dvl hyper ubiqui-
tination, resulting in the transmission of Wnt signaling to 
downstream effectors. β-catenin upregulation is observed 
during disease progression in chronic myeloid leukemia 
(CML). Deregulated Dvl signaling may be a reason for 
β-catenin activation in CML; and CYLD may contribute to 
Dvl deregulation. First, we evaluated mRNA expression in 
three CML cell lines and mRNA expression of the CYLD 
gene was found to be present in all (K562, MEG01, KU812). 
Unlike solid tumors sequencing revealed no mutations in 
the coding sequences of the CYLD gene. DVL genes were 
silenced by using a pool of siRNA oligonucleotides and gene 
expression differences in CYLD was determined by RT-PCR 
and western blot. CYLD protein expression decreased after 
Dvl silencing. An opposite approach of overexpressing Dvl 
proteins resulted in upregulated CYLD expression. While 
previous reports have described CYLD as a regulator of 
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CYLD itself is constitutively active and its deubiquitinase 
domain has specificity for Lys63 chains. CYLD binds to 
Dvl and mediates its ubiquitination. While ubiquitination of 
Dvl proteins results in β-catenin accumulation (by inhibit-
ing the β-catenin destruction complex), de-ubiquitination by 
CYLD will lower β-catenin levels in the cytoplasm. Several 
reports have shown that silencing/depleting CYLD leads 
to β-catenin accumulation in the cytoplasm, Wnt/β-catenin 
signaling activation and the hyper ubiquitination and over-
expression of Dvl proteins [11]. Genetic aberrations and 
reduced expression of CYLD has been reported in several 
solid tumors [12, 13]. Sequence changes can occur by frame 
shift, nonsense, missense and splice-site mutations [14]. 
Recent studies reveal that CYLD deficiency may promote 
the generation of different solid tumors. Interestingly we 
have little knowledge on CYLD expression and function in 
hematological malignancies.
The first description of deregulated Wnt signaling in a 
hematological malignancy was reported in chronic myeloid 
leukemia (CML) [15]. CML is a clonal hematopoietic stem 
cell (HSC) disorder, characterized by unregulated growth 
of myeloid lineage cells. The hallmark of the disease is the 
reciprocal translocation between the long arms of chromo-
somes 9 and 22 that results in a BCR-ABL chimeric gene 
[16]. The product of this gene is a constitutively active tyros-
ine kinase which provides a survival signal for the cell [17]. 
Studies have reported activated Wnt signaling in all stages of 
CML and demonstrated that activation of the pathway plays 
an important role in disease pathogenesis. A previously 
uninvestigated underlying mechanism of β-catenin hyper 
activation would be the possibility deregulation of Dvl pro-
teins through CYLD. In this study we aimed to investigate 
CYLD gene mutations in CML cell lines and to explore the 
interaction between Dvl and CYLD proteins.
Materials and methods
Cell culture
BCR/ABL positive cell lines K562, MEG01 and KU812 
were purchased from DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH). Cell lines were 
grown in RPMI-1640 medium containing 10% fetal bovine 
serum, 2 mM l-glutamine, 1 μg/ml penicillin. All cultures 
were incubated at 37 °C in a humidified incubator with 5% 
 CO2. Cells were counted by Cell Scapter2.0 (Millipore, Bill-
erica, MA).
RNA extraction, RT‑PCR and real time PCR
Total RNA extractions were done by using the RNeasy Plus 
Mini Kit (Qiagen, Hilden), according to the manufacturer’s 
instructions. cDNA was synthesized by using Transcriptor 
First Strand cDNA Synthesis Kit (Roche, Mannheim, Ger-
many). Different sets of primer pairs were used for quan-
titative expression analysis. β-actin was used as internal 
control. For the expression analysis of CYLD gene, primer 
sequences are shown in Table 1. The thermal profile for 
CYLD expression initiated with a 10 min, 95 °C denatura-
tion step, followed by 35 cycles of 5 s at 95 °C (denatura-
tion); 10 s at 55 °C (annealing); and 15 s at 72 °C (exten-
sion). Each experiment was done in triplicate.
Sequencing of coding region of CYLD
The CYLD gene encodes 20 exons. Mutational hotspots 
frequently occur between exons 9–20. The CYLD cod-
ing sequences were amplified by PCR using 6 primer 
pairs covering all exons of the human CYLD gene. Primer 
sequences are listed in Table 2. The thermal profile for the 
PCR reactions is as follows: 10 min, 95 °C denaturation 
step, followed by 40 cycles of 15 s at 95 °C for denaturation 
and 1 min at 60 °C for annealing. All PCR samples were 
run in 1% agarose gel. PCR products were sequenced by 
Table 1  Primer sequences for mRNA expression of CYLD and 
β-actin
Primer sequences Length of 
PCR product 
(bp)
β-actin 318
 F: ATC ATG TTT GAG ACC TTC AA
 R: CAT CTC CTG CTC GAA GTC CA
CYLD 627
 F: TGA GAA AGT TGG CGT TCC CACA
 R: GCA GTC TTC GTG CAC AGC CTTG
Table 2  6 pairs of primer sequences were used in mutational analy-
sis of CYLD
Primer sequences Length of 
PCR product 
(bp)
F1: AGT TCA GGC TTA TGG AGC CAAG
R1: GAC CAC GAC CTT CTT CCA GCAA
517
F2: CGC TTC AGA GGA CCC CTG TTA
R2: TTC ACA GGA GGA GGC TGG AGTG
785
F3: GCC TCC CAA ACT TGC CTT TAT
R3: AGT GCC TCT GAA GGT TCC ATCC
620
F4: TCG CTG GAC TGG AAC TGG AAGA
R4: GCC CTC CAC ATA TAC CGG CAC
879
F5: TGA GAA AGT TGG CGT TCC CACA
R5: GCA GTC TTC GTG CAC AGC CTTG
627
F6: AGT CAC CCC ATG CCC AGA AGT
R6: TTC CTC AAG GCA ACC GTT AGC
582
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bi-directional sequencing (Macrogen, Amsterdam, Nether-
land). Sequence results were compared with CYLD mRNA 
reference sequence (NM_015247.2).
Silencing of Dvl genes
BLOCK-iT™ RNAi Designer software (Invitrogen) was 
used to design Dvl1, Dvl2, and Dvl3 siRNA targets approx-
imately 20 bp long. Single strand siRNA oligonucleotides 
were annealed in a 1× annealing buffer (1 M Tris, pH 8.0, 
0.5 M EDTA, 5M NaCl, DNase/RNase free  dH2O). A pool 
of Dvl siRNA oligonucleotides were transfected into cells 
by electroporation (Neon Transfection System, Invitrogen). 
100 pmol equally mixed siRNA oligonucleotides were added 
to a homogenized cell pellet of 5 × 105 cell/ml density in a 
micro centrifuge tube. The cell pellet was re-suspended with 
Resuspension Buffer R. Transfected cell suspensions were 
added to antibiotic free 10% FBS containing RPMI1640 
cell medium. Cells were incubated for 48 h before analy-
ses. Input values for the electroporation of each cell line 
are 1450 V, 10 ms, 3 pulses. Scrambled RNA was used as 
non-target RNAi control. Transfected siRNA sequences are 
given in Table 3.
Protein extraction and western blotting
MEG01 cells were grown to 80% confluency. After 48 h, 
siRNA treated and untreated cells were washed with ice 
cold PBS and lysed using PYLB buffer containing 50 mM 
HEPES (pH 7,6), 50  mM NaF, 5  mM EDTA, 10  mM 
Sodium pyrophosphate (NaPPi), 1% Triton-X, 50 mM 
NaCl, protease and phosphatase inhibitors (Applichem 
GmbH, Germany). Cell lysates were centrifuged at 
14,000 rpm for 15 min. Protein concentration was meas-
ured by Bradford assay method (Applichem, Darmstadt, 
Germany). β-actin was used as a loading control. About 
30 μg of protein was loaded in to each well of an 10% 
SDS-PAGE gel. For lysates of cells overexpressing Dvl 
proteins, only 20 μg of protein was loaded. Gel electropho-
resis was run at 100 V for 1 h. Proteins were transferred 
to a polyvinylidene difluoride membrane (PVDF) and 
then blocked with 5% nonfat dried milk powder at room 
temperature for 1 h. Membranes were incubated overnight 
at 4 °C with β-actin (1/1000, Cell Signaling Technolo-
gies), CYLD (1/1000, Cell Signaling Technologies), Dvl1, 
Dvl2 and Dvl3 (1/1000, Santa Cruz) antibodies. Goat anti-
rabbit and goat anti-mouse secondary antibodies were 
used against first antibody (Cell Signaling Technologies, 
1/10,000). Prestained Protein Ladder was used (Thermo 
Fisher Scientific #26619c). Protein bands were detected 
by Luminata Forte Western HRP Substrate (Millipore, 
Billerica, MA). Densitometric analysis of detected protein 
bands were performed by ImageJ software (http://imagej.
nih.gov/ij/).
Overexpression of Dvl2 and Dvl3 genes
Dvl2 and Dvl3 genes were cloned into the eukaryotic 
expression vector pEGFP-C1 and transfected into MEG01 
cells by electroporation. 70–80% confluent cells were 
seeded in a 6 well plate. Plating medium was 2 ml and 
the cells were cultured in an antibiotic free RPMI1640. 
pEGFP-C1-Dvl2/ pEGFP-C1-Dvl3 vectors were equally 
mixed (1:1) and transiently transfected by electroporation. 
0,5 µg/ml empty pEGFP-C1 vector was also transfected as 
control. The same electrical force mentioned previously 
was applied to the cells. After electroporation cells were 
incubated for 48 h before analyses. Transfection efficiency 
was determined by DIC microscope (Olympus) and West-
ern Blot.
Immunofluorescence analysis
Cells were fixed with 4% paraformaldehyde for 15 min and 
permeabilized in 0.1% Triton-x for 15 min on ice. Block-
ing was carried out in 1% BSA for 1 h at room tempera-
ture. Cells were incubated with Dvl2 (Santa Cruz, 1/1000) 
and β catenin (BD, 1/1000) primer antibodies. Green fluo-
rescent dye conjugated secondary antibodies were added 
to label the indicated proteins (Invitrogen, Alexa Fluor488 
goat anti mouse and rabbit). Nuclei were counterstained 
with DAPI (Applichem).
Table 3  siRNA and non-
targeting siRNA sequences used 
in Dvls silencing
Gene name (RefSeq) siRNA sequence Binding sequence Exon
Dvl1 (NM_004421) 5′-AAG AUU AUC UAC CACAUtt-3′
3′-ggUUC UAA UAG AUG GUGUA-5′
58–78 1
Dvl2 (NM_004422) 5′-GUC AAC AAG AUC ACCUUtt-3′
3′-ggCAG UUG UUC UAG UGGAA-5′
1754–1774 13
Dvl3 (NM_004423) 5′-GUC AAC AAG AUC ACCUUtt-3′
3′-ggCAG UUG UUC UAG UGGAA-5′
1579–1599 13
ScrambledsiRNA 5′-GAC AAU AGA CAC CUCUUtt-3′
3′-ggCUG UUA UCU GUG GAGAA-5′
– –
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Results
CYLD mRNA is expressed in CML cell lines
Previous studies have shown that activation of the Wnt 
signalling pathway plays a key role in disease progression 
to blastic phase. In aim to investigate the possibility of 
β-catenin activation in blastic phase CML due to deregu-
lation of Dvl proteins through CYLD; we first determined 
whether CYLD was expressed in blastic phase CML cells. 
K562, MEG01 and KU812 cells were analyzed by RT-PCR 
for CYLD mRNA expression. All three blastic phase CML 
lines were shown to express the CYLD gene (Fig. 1).
Mutational analysis of CYLD coding region in CML 
cell lines
Total RNA was extracted and converted to cDNA from 
K562, MEG01 and KU812 cell lines and PCR was per-
formed using the specific primers given in Table 2. We used 
6 primer pairs to cover the coding sequences of the CYLD 
gene. Primers were designed from exon–exon junction 
regions to eliminate false positive results caused by genomic 
DNA contamination. PCR products were sequenced bi-
directionally. We determined that none of the cell lines carry 
mutations in the coding region of the CYLD gene.
Effect of silencing Dvl1, ‑2, ‑3 proteins on β‑catenin 
subcellular localization and CYLD protein levels
Dvl1, -2, -3 genes were silenced by siRNA oligonucleo-
tides in MEG01 cells. Cells were collected after 48 h fol-
lowing transfection and protein expression was analyzed. 
Dvl genes were shown to be downregulated successfully in 
MEG01 cells (Fig. 2a). Interestingly a 53% reduction was 
observed in CYLD protein expression at the 48th hour in 
Dvl siRNA transfected cells when compared to scrambled 
siRNA transfected controls (Fig. 2b). The effect of silenc-
ing Dvl proteins on β-catenin was investigated by immu-
nofluorescent microscopy. Neither an increase in β-catenin 
protein levels; nor a change in subcellular localization was 
observed in cells transfected with Dvl pool siRNA (Fig. 3), 
confirming that the Wnt/β-catenin canonical pathway has 
not been activated by the procedure. While previous reports 
have described CYLD as a regulator of DVL proteins; our 
data suggests the presence of a more complicated reciprocal 
regulatory mechanism.
Effect of Dvl2 and Dvl3 overexpression on CYLD 
protein level
Dvl2 and Dvl3 genes were cloned into a pEGFP-C1 vec-
tor and overexpressed after being transfected into CML cell 
Fig. 1  K562, MEG01and KU812 cell lines express CYLD mRNA. 
CYLD mRNA expression was assessed in three different CML cell 
lines. PCR results showing CYLD (1 K562, 2 MEG01, 3 Ku812) and 
β-actin (4 K562, 5 MEG01, 6 KU812) gene expression on 1% aga-
rose gel. β-actin was used as loading control (bands; CYLD: 627 bp, 
β-actin: 318  bp; M-Marker: O’ Range Ruler 1  kb DNA ladder-
Thermo Scientific)
Fig. 2  Silencing Dvl proteins decreases CYLD expression as shown 
by Western blot. a A significant decrease in Dvl genes were observed 
after Dvls silencing in MEG01 cell line. b CYLD protein was shown 
by Western blot in MEG01 cells and control scrambled RNAi vector 
transfected cell lines (CYLD primer antibody, 1/1000, Cell Signaling 
Technologies). A decrease in CYLD protein level was observed after 
Dvl1, -2, -3 genes silencing when compared with control. Primary 
antibodies used: β-actin (1/1000, CST), Dvl1, 2, 3 (1/1000, Santa 
Cruz)
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lines. Transfection efficiency was monitored using a fluores-
cence microscope and cells transfected with empty control 
and DVL-pEGFP-C1 vectors both were observed to express 
EGFP protein at high levels. Dvl2 and Dvl3 protein expres-
sion was confirmed by western blot (Fig. 4a). A significant 
increase in expression of Dvl2 and Dvl3 proteins were 
observed in DVL-pEGFP-C1 transfected cells when com-
pared with the controls. CYLD protein expression paralleled 
that of the Dvl proteins and was shown to be upregulated 
54% with Dvls overexpression (Fig. 4b), again supporting 
the presence of a reciprocal regulatory mechanism between 
these proteins.
Discussion
β-catenin/Wnt signaling pathway is crucial for embryo-
genesis, development, cell proliferation, differentiation, 
self-renewal and homeostasis [1]. Pathway activation 
leads to β-catenin being stabilized and its accumulation 
in the cytoplasm and translocation to the nucleus where 
it regulates the activity of several transcription factors. 
Following the binding of specific Wnt ligands with their 
partner Frizzled (Fz) receptors, one of the first steps of 
the signaling pathway is Fz receptor-mediated plasma 
membrane recruitment and activation of the cytoplasmic 
effector Dishevelled (Dvl). Dvl proteins play central role in 
relaying Wnt signals from the plasma membrane to differ-
ent cytoplasmic effectors [18]. In mammals there are three 
members of Dvl family: Dvl1, -2 and -3 [19]. They are 
activated by phosphorylation in response to Wnt signal-
ing; whereas the ubiquitination of Dvl proteins leads to an 
effective inhibition of the β-catenin destruction complex 
[20]. Dvl ubiquitination can be antagonized by various 
de-ubiquitinases including the CYLD tumor suppressor 
protein, resulting in inhibited Wnt signaling. CYLD, has 
Fig. 3  Immunofluorescence microscopy images of β-catenin locali-
zation before and after silencing Dvl proteins. Following silencing of 
Dvl proteins in MEG01 cells, cytoplasmic localization of and expres-
sion level of β-catenin is not altered; showing that the Wnt/β-catenin 
canonical pathway has not been activated following siRNA transfec-
tion. Nucleus stained with DAPI; (β-catenin antibody, BD Transduc-
tion Laboratories Cat No: 610153)
Fig. 4  CYLD expression 
increases with Dvl2 and Dvl3 
overexpression. a Dvl2 and 
Dvl3 genes cloned in to pEGFP 
vector are overexpressed fol-
lowing transfection The lower 
band observed at the same 
height when compared to the 
control represent the cellular 
Dvl2 and Dvl3 proteins; while 
the upper band with a higher 
molecular weight corresponds 
to the transfected Dvl proteins 
containing the GFP tag. b 
Protein expression of CYLD is 
upregulated with Dvl2 and Dvl3 
over-expression
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been defined as a tumor suppressor gene, and a negative 
regulator of in Wnt/beta-catenin signaling that regulates 
Dvl activity [11].
CYLD was originally reported as a tumor suppressor gene 
[9] that is mutated in familial cylindromatosis, a rare auto-
somal dominant disorder associated with numerous benign 
skin tumors. It was shown to regulate cell proliferation and 
survival. CYLD is known to interact with several proteins 
such as TNF-receptor-associated factor proteins and NEMO 
protein [14]. The CYLD gene product is a deubiquitinat-
ing enzyme that has specificity for Lys63 chains. CYLD is 
now known to regulate various signaling pathways such as 
Wnt/β-catenin signaling, NF-κB signaling, TGF-β signaling, 
Bcl2 signaling and the MAPK pathway, by deubiquitinating 
upstream regulatory factors. Downregulation of CYLD has 
been reported in several types of cancer including lung [21], 
breast [22], skin cancers [23], colon cancer, hepatocellular 
carcinomas [24] and multiple myeloma [25]. A close relation 
between CYLD and Dvl-linked Wnt signaling was defined 
by Taurello et al. [11]. They reported that CYLD depletion 
leads to hyper ubiquitination of Dvl proteins and Wnt path-
way activation, resulting in β-catenin overexpression which 
in turn could lead to tumorigenesis and/or progression of 
an existing malignancy. However, the role and significance 
of CYLD expression in myeloid malignancies, including 
chronic myeloid leukemia (CML) has not been investigated 
and is thus unknown.
CML is a triphasic myeloproliferative disorder clinically 
characterized by an initial chronic phase which progresses 
to an accelerated phase and terminally blast crisis [26]. The 
hallmark of the disease is the t(9;22) (q34;q11) translocation 
[27] which results in the formation of a BCR/ABL fusion 
gene [28]. The Bcr/Abl oncoprotein is a constitutively active 
tyrosine kinase causing the unregulated activation of several 
signaling pathways [29]. CML was the first hematological 
malignancy in which aberrant Wnt/β-catenin signaling was 
first defined [15], and in which β-catenin over-expression 
was shown to be responsible for blastic transformation, dis-
ease progression and resistance to therapy [17].
In the present study we aimed to investigate the role 
CYLD had -if any- in Dvl mediated β-catenin signaling 
in CML cell lines K562, MEG01 and KU821. All three 
cell lines are obtained from patients in blastic crisis. We 
first evaluated CYLD mRNA expression and showed that 
all three cell lines express CYLD. To exclude the pos-
sibility of any mutations in the CYLD coding sequence, 
mutational analyses were performed and we showed that 
the CYLD gene did not carry any mutations in its cod-
ing sequences in K562, MEG01 and KU821 cell lines. 
Our data shows that CYLD is expressed in CML cell lines 
and its coding sequence is not mutated; indicating that the 
CYLD gene may not play a role in unregulated Wnt signal-
ing observed in CML. In the literature CYLD mutation/
aberrations has been associated with different types of can-
cer; on the contrary we couldn’t observe any aberrations 
in CML cell lines.
Dvl-CYLD protein interactions were reported by sev-
eral studies, defining CYLD as a regulator of Dvl proteins 
through de-ubiquitination. We silenced Dvl genes with 
siRNA oligonucleotides in MEG01 cells. Interestingly 
CYLD mRNA and protein expression was also shown to be 
downregulated over twofolds in Dvl siRNA transfected cells 
when compared to scrambled siRNA transfected controls. 
While previous reports have described CYLD as a regu-
lator of Dvl proteins; our data suggests the presence of a 
more complicated reciprocal regulatory mechanism. In an 
opposite approach we overexpressed Dvl genes and observed 
that CYLD protein expression also increased. The positive 
correlation between the expression patterns of CYLD and 
Dvl protein supports the presence of a complex modulatory 
mechanism in which the expression of both genes have a 
positive regulatory effect on each other. Although previous 
reports have shown Dvl regulation by CYLD, this is the first 
study to suggest that the observed regulatory function may 
be reciprocal. Our data reveals another layer of complexity 
in the function of Dvl proteins in which further research will 
be required to understand its interactions with CYLD.
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